ETHNIC FEATURES OF CARRIER OF COMBINATIONS OF CYP2C9 AND VKORC1 GENOTYPES AMONG PATIENTS WITH A CARDIOEMBOLIC ISCHEMIC STROKE
- Authors: Nikolaeva T.I.1, Everstova T.E.1, Chugunova S.A.1, Chertovskikh L.V.2, Popova N.V.2
-
Affiliations:
- Ammosov North-Eastern Federal University
- Republican Clinical Hospital №3
- Issue: Vol 22, No 2 (2020)
- Pages: 9-12
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95175
- DOI: https://doi.org/10.26442/20751753.2020.2.200033
- ID: 95175
Cite item
Full Text
Abstract
Aim. To study the ethnic characteristics of the carriage of combinations of genotypes of the CYP2C9 and VKORC1 genes among patients with cardioembolic ischemic stroke. Materials and methods. We studied patients with ischemic stroke of the cardioembolic type in the acute stage on the background of atrial fibrillation and/or prosthetic heart valves, belonging to the Asian (first group) or Caucasian race (second group). The identification of the carriage of CYP2C9*1 polymorphisms («wild type») CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910) of the CYP2C9 gene, and variants of the G3673A (rs9923321) polymorphism of the VKORC1 gene was carried out using the polymerase chain reaction method. Results. Among patients of the Asian race, in 86.9% of cases, carriage of combinations of the CYP2C9 and VKORC1 genotypes was identified, associated either with a slowed metabolism or with increased sensitivity to warfarin. In the group of patients of the Caucasian race, the proportion of carriers of the CYP2C9 and VKORC1 genotypes was significantly less and amounted to 55% (p=0.0001). Conclusion. The results confirm the need for lower doses of warfarin in the group of people of the Asian race to prevent hemorrhagic complications without increasing the risk of thromboembolic events.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Tatiana Ia. Nikolaeva
Ammosov North-Eastern Federal University
Email: tyanic@mail.ru
д-р мед. наук, зав. каф. неврологии и психиатрии Yakutsk, Russia
Tatiana E. Everstova
Ammosov North-Eastern Federal Universityаспирант каф. неврологии и психиатрии Yakutsk, Russia
Sargylana A. Chugunova
Ammosov North-Eastern Federal Universityканд. мед. наук, доц. каф. неврологии и психиатрии Yakutsk, Russia
Lana V. Chertovskikh
Republican Clinical Hospital №3глав. внештатный клинический фармаколог Минздрава Республики Саха Yakutsk, Russia
Niurguiana V. Popova
Republican Clinical Hospital №3врач - клинический фармаколог Yakutsk, Russia
References
- Guidelines for the Primary Prevention of Stroke. A Statement for Healthcare Professionals From the American Heart Association /American Stroke Association. Stroke 2014; 45 (12): 3754-832. doi: 10.1161/STR.0000000000000046
- Сычев Д.А. Рекомендации по применению фармакогенетического тестирования в клинической практике. Качественная клиническая практика. 2011; 1: 3-10. @@Sychev D.A. Rekomendatsii po primeneniiu farmakogeneticheskogo testirovaniia v klinicheskoi praktike. Kachestvennaia klinicheskaia praktika. 2011; 1: 3-10 (in Russian).
- Liu T, Hui J, Hou YY et al. Meta-Analysis of Efficacy and Safety of Low-Intensity Warfarin Therapy for East Asian Patients With Nonvalvular Atrial Fibrillation. Am J Cardiol 2017; 120 (9): 1562-7. doi: 10.1016/j.amjcard.2017.07.050
- Голухова Е.З., Арсланбекова С.М., Сычев Д.А. Фармакогенетические основы, определяющие нежелательные лекарственные реакции у кардиохирургических больных, принимающих варфарин. Креативная кардиология. 2011; 1: 20-7. @@Golukhova E.Z., Arslanbekova S.M., Sychev D.A. Farmakogeneticheskie osnovy, opredeliaiushchie nezhelatel'nye lekarstvennye reaktsii u kardiokhirurgicheskikh bol'nykh, prinimaiushchikh varfarin. Kreativnaia kardiologiia. 2011; 1: 20-7 (in Russian).
- Visser LE, Schaik RH, Vliet MM et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9‘2 or CYP2C9'3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61-6.
- Chern HD, Ueng TH, Fu YP, Cheng CW. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. 2006; 367: 108-13.
- Lal S, Sandanaraj E, Jada SR et al. Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br J Clin Pharmacol 2008; 65: 260-4.
- Ngow H, Wan Khairina W, Teh L et al. CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Med J 2009; 50: 490-3.
- Hamberg AK, Wadelius M, Lindh JD et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 2010; 87: 727-34.
- Loebstein R, Vecsler M, Kurnik D et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005; 77: 365-72.
- Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-92.
- Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63: 1135-41.
- Tang W, Shi OR Ding F et al. Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies. Int J Clin Pharmacol Ther 2017; 55 (4): 304-21. doi: 10.5414/CP20283
- Зотова И.В., Никитин А.Г., Фаттахова Э.Н. и др. Влияние полиморфизма генов CYP2C9 и VKORC1 на безопасность терапии варфарином. Клиническая практика. 2013; 4: 3-10. @@Zotova I.V., Nikitin A.G., Fattakhova E.N. et al. Vliianie polimorfizma genov CYP2C9 i VKORC1 na bezopasnost' terapii varfarinom. Klinicheskaia praktika. 2013; 4: 3-10 (in Russian).
- Lam M, Cheung B. The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol 2012; 73 (3): 340-7. doi: 10.1111/j.1365-2125.2011.04097.x
- Сычев Д.А., Михеева Ю.А., Кропачева Е.С. и др. Влияние полиморфизма гена CYP2C9 на фармакокинетику и фармакодинамику варфарина у больных с постоянной формой фибрилляции предсердий. Клиническая медицина. 2007; 1: 57-60. @@Sychev D.A., Mikheeva Iu.A., Kropacheva E.S. et al. Vliianie polimorfizma gena CYP2C9 na farmakokinetiku i farmakodinamiku varfarina u bol'nykh s postoiannoi formoi fibrilliatsii predserdii. Kli-nicheskaia meditsina. 2007; 1: 57-60 (in Russian).
- Owen RP, Gong L, Sagreiya H et al. VKORC1 Pharmacogenomics Summary. Pharmacogenetics Genomics 2010; 20 (10): 642-4. doi: 10.1097/FPC.0b013e32833433b6
- Rieder MJ, Reiner AP, Gage BF Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose et al. N Engl J Med 2005; 352 (22): 2285-93. doi: 10.1056/NEJMoa044503
- Загорская В.Л., Игнатьев И.В., Кропачева Е.С. и др. Полиморфный маркер G3673A гена VKORC1 - новый генетический фактор, ассоциированный с развитием геморрагических осложнений при применении непрямых антикоагулянтов. Клиническая фармакология и фармакоэкономика. 2008; 1: 29-33.
